StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Free Report) in a report released on Monday. The brokerage issued a sell rating on the stock.
NovaBay Pharmaceuticals Price Performance
NBY opened at $0.08 on Monday. The firm has a market cap of $2.93 million, a price-to-earnings ratio of -0.02 and a beta of 1.97. NovaBay Pharmaceuticals has a 1 year low of $0.07 and a 1 year high of $1.95. The stock’s 50 day simple moving average is $0.13 and its 200 day simple moving average is $0.22.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.95) earnings per share for the quarter. The business had revenue of $3.73 million during the quarter. NovaBay Pharmaceuticals had a negative return on equity of 150.14% and a negative net margin of 65.46%. As a group, sell-side analysts anticipate that NovaBay Pharmaceuticals will post -0.41 EPS for the current year.
Institutional Investors Weigh In On NovaBay Pharmaceuticals
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Further Reading
- Five stocks we like better than NovaBay Pharmaceuticals
- Consumer Staples Stocks, Explained
- United Airlines Soars on Earnings Beat
- Basic Materials Stocks Investing
- J.B. Hunt Hits the Skids: Lower Prices to Come
- How is Compound Interest Calculated?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.